Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Average Recommendation of “Hold” from Analysts

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have earned an average rating of “Hold” from the thirteen research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $27.36.

A number of equities research analysts recently issued reports on DCPH shares. Stifel Nicolaus cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the company from $60.00 to $10.00 in a research note on Sunday, November 7th. lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $72.00 to $12.00 in a report on Monday, November 8th. Truist Securities lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $65.00 to $10.00 in a report on Friday, November 5th. Truist lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $65.00 to $10.00 in a report on Friday, November 5th. Finally, HC Wainwright reduced their price target on Deciphera Pharmaceuticals from $25.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, December 1st.

NASDAQ:DCPH traded down $0.02 during midday trading on Friday, hitting $8.39. The company’s stock had a trading volume of 21,391 shares, compared to its average volume of 2,429,650. Deciphera Pharmaceuticals has a fifty-two week low of $7.63 and a fifty-two week high of $52.67. The firm’s 50 day moving average is $9.14 and its 200-day moving average is $24.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Tuesday, November 2nd. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.29) by ($0.08). The firm had revenue of $23.22 million for the quarter, compared to analyst estimates of $23.73 million. Deciphera Pharmaceuticals had a negative return on equity of 58.56% and a negative net margin of 300.00%. During the same period in the previous year, the business earned ($1.13) EPS. Equities research analysts predict that Deciphera Pharmaceuticals will post -5.14 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Weiss Multi Strategy Advisers LLC grew its position in shares of Deciphera Pharmaceuticals by 3.7% in the 2nd quarter. Weiss Multi Strategy Advisers LLC now owns 10,480 shares of the company’s stock worth $384,000 after acquiring an additional 374 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Deciphera Pharmaceuticals by 1.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,681 shares of the company’s stock worth $830,000 after purchasing an additional 401 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Deciphera Pharmaceuticals by 69.7% in the 2nd quarter. Lazard Asset Management LLC now owns 1,739 shares of the company’s stock worth $63,000 after purchasing an additional 714 shares during the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Deciphera Pharmaceuticals by 90.8% in the 2nd quarter. Macquarie Group Ltd. now owns 2,005 shares of the company’s stock worth $73,000 after purchasing an additional 954 shares during the last quarter. Finally, Cohanzick Management LLC lifted its holdings in shares of Deciphera Pharmaceuticals by 25.0% in the 2nd quarter. Cohanzick Management LLC now owns 5,000 shares of the company’s stock worth $183,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors own 78.98% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.

Recommended Story: What is a dividend reinvestment plan?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.